To The Moon

Sign Up
  • 1
  • 2
  • Favorite

Incannex Healthcare reports Phase 2 data showing IHL-42X reduces AHI in obstructive sleep apnoea

Reuters11-20

<a href="https://laohu8.com/S/IHLXF">Incannex Healthcare</a> reports Phase 2 data showing IHL-42X reduces AHI in obstructive sleep apnoea

Incannex Healthcare Inc. reported quarter-end cash of $73.3 million, a net loss of $6.4 million, and operating expenses of $6.8 million, supporting at least twelve months of financial runway. During the period, the company advanced its clinical programs, including significant progress with IHL-42X for obstructive sleep apnoea, which showed up to 83.0% reduction in Apnoea-Hypopnoea Index in Phase 2 trials, and PSX-001, which demonstrated meaningful anxiety reduction in Phase 2. Preparations are underway for FDA interactions and further clinical studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 275311) on November 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（2）

  • Hao1
    ·11-21
    $INCANNEX HEALTHCARE LTD(IXHL)$ This is very important news, and it is one of the BEST pieces of clinical news IXHL has released in a long time. Let me break it down carefully and simply for you: ⭐ 1. Phase 2 data CONFIRMS the drug actually works This line is HUGE: “IHL-42X showed up to an 83% reduction in AHI in Phase 2 trials.” AHI = the number of times your breathing stops per hour. 👉 83% improvement is extremely strong. 👉 This means many patients had almost normal breathing during sleep. This is NOT small improvement. This is life-changing level improvement. For sleep apnea patients, this is VERY meaningful. --- ⭐ 2. This makes IHL-42X one of the most promising oral treatments in the world Today, sleep apnea treatment options are mostly: CPAP (hard to tolerate) Surgery (risky) Devices
    Reply
    Report
  • breAkdaWn
    ·11-21
    5 years waiting period.  by then will probably delist!
    Reply
    Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

All